Member Info for SiriusB

Casajuma, are you saying because you called a placing on some AIM tiddler you know what is going to happen with the RR share price? Small cap companies on AIM do placings all the time. It’s how they fund their business. Funniest thing I’ve read in a long time.

You may be right with RR but you may be wrong. You are just guessing. It will take some pretty bad news or a market correction to sink RR to 200p by the end of July. Given we just had a trading update on Thursday it would have to be something no one can see coming...

What’s lead you believe that AW as I’ve not seen any news to confirm your view? Most on here said a LFT out by end of Aug. I think you suggested September.

As news on progress is released through July and August to the point the test is on the market do you think the sp will be higher or lower over that time?

Whilst we all want the sp to rise and do well so we can get an increasing return on our investment some (mainly just Global) are missing the big picture here. The sp will go up and down, it’s what it does. Instead of focusing on the hour by hour sp movements focus on what the company is developing and where we are against those development milestones. Getting distracted by the sp some are missing the huge opportunity here that is staring them right in the face!

Chengdo, that would be the big one. Huge market, massive problems there and plenty of money to buy tests. I think it may take some time to get that deal done around FDA approval. The US market can be a tough nut to crack as I’m seeing on a couple of my other holdings.

Well I count 2 swords and potentially four revenue streams for Covid then:
Mass screening LFT
A better than gold standard BAMS test
Therapy
And today, waste water testing

Strong near term news flow!

Kong, suggest you read the RNSs on 15th May and 18th June exciting stuff for sure

NK, I’m not sure any sensitivity and specificity data will be released when the prototype is ready. At least is wasn’t for the BAMS test. If it was it would potentially light a rocket under the sp, given what AS has alluded to being achievable, but I expect that data to be released after the clinical validation (more meaningful and what will be used to approve the test). I expect the next LFT RNS to say prototype ready, partner(s) signed up and tech transfer starting whilst clinical validation in process. AS might say the test meets the expectations but then we already have been told this. I’m intrigued to see who the UK manufacturing partner(s) is/are more than anything. As AS has stated it’s all just a process now the hard work is done and the test works.

Good point about the timing of the engagement with Ruane Skivy. AS said he’d been meeting with them for a while, certainly pre Covid. To think they were doing there due diligence then and decided to take a position at a 600% premium to when they must have started tells us something. At 120p Ruane see Avacta as a value investment. I couldn’t agree more!

Good summary of the Washington Post article on Ruane Schrow. The due diligence that has gone into the investment in Avacta is very significant. Avacta now join the list of only 18 companies in the Conifer fund according to the last 13F filing. I am hoping that the £10m taken in the placing was just the start of a stake building and they continue to add in the future.

Hi all, not been posting on here as we are just waiting for news from Avacta on the Covid BAMS, LFTs and treatment now. Still reading the board and there have been some quality discussions on here that have been good to read over the last week. I also get some weird enjoyment from reading the deramping posts in the morning that never age well and following Global’s incredible trading talents. I simply don’t have time nor the inclination to trade any of my holding.

Going off the topic of Avacta, and for those following the EUA story (no cross-ramp intended), I’ve been reflecting on my strategy to hold here. Whilst we’ve probably all got stories to tell of what might have been chasing the rabbit with the power of hindsight my impatience, with the specific example of EUA, has cost me big time. I believed in the fundamental value story but I couldn’t get behind the board there so sold out at the end of last year. A good profit I thought. Ironically the trading suspension would have worked wonders for my portfolio as I only lost money as Covid took hold and impacted the shares where I had put that cash. My £35k stake would be worth £250k today. The suspension and in effect forced hold has worked out very well for those invested. My reflection has been to stick with my conviction and hold when I see huge upside in the value based on clear fundamentals. In the case of Avacta I am even more confident as I also fully trust the board to deliver what they say they will given their communications to date (I even accept the 120p placing). Whilst different industries, risks, etc and no two companies are alike I won’t be making the same mistake here and selling before the true long term value I perceive has been realised.

Well done all in here. Great to see a winner on AIM. I bought 1.4m shares back in Nov at 2.7p Unfortunately I sold them in December at 3.3p :-(

I liked the story but struggled to get behind the board. My loss. Good luck although a think you’ll continue to do well from here

Ricky, there is no requirement for a ftse Company to report quarterly. RR report their results every 6 months. The update tomorrow is just a trading update of which we are receiving more in this current environment. Whilst I am neutral on RR at the moment, given I don’t see people flying long haul much at the moment or in the near future, a lot of your points are just your wild ‘glass half empty’ opinion and not facts.

Sounds like you are trying to trade it if you were to do that. Focus on the underlying market. Are less or more people going to be flying over the next few months? How long will people avoid long haul flying. Based on this buy in when you think the worst is over (perhaps that’s in the past) and hold over the next 3-5 years as the company recovers. You might be able to trade it by guessing and getting lucky but most lose money

I don’t think it’s a u turn. No one has been able to predict the short to medium term outlook since the coronavirus in the aero industry. It was initially much worse than expected and now is looking like it’s going to take longer to recover than first thought. Hindsight is a fantastic thing but the board are making decisions and planning based on what they know today. It’s all about flying hours. Focus on this first and the sp will follow suit

Amazing to see Sona sp react so positively to just lab data. I think AS does a fantastic job at focusing on delivering results and not hyping the sp. He’s very measured in what he says. To think that Sona hit a MCap of £230m on open vs Avacta’s £300m today. And we’ve got affimers instead of someone else’s antibodies in the LFT, a second test (BAMS), possible treatment, pre Cision, TMAC and various other partnerships/JVs. Not to mention affimers advantages over antibodies (affinity, speed to make, etc). Some of the valuations for Avacta based on the market may not seem so crazy in a few weeks time

KSH321 there has been no delay.

Nice find PAH00. Thanks for sharing. Those lab results look promising. I agree that the Sona CEO sounded much less confident than DW from Avacta on sensitivity. Bodes well for some very good sensitivity and specificity results from Avacta. It’s all about the clinical validation results though. Exciting times. Sona certainly keep the market/investors up to date on all test results as get them

RK, are you suggesting the market in the workplace won’t be there given the tests expected pricing (already discussed by AS in an early interview)? I think £10 on wholesale volume absolute minimum and £25 for consumers. My view is the workplace usage will depends on the workplace risk, screening population size, frequency, etc. Yes I don’t think large manufacturing organisations are going to start spending £10m a year on testing when the controls in place sufficiently reduce the risk but high risk workplaces will have no choice. The testing/screening strategy of each type of customer is an interesting point that hasn’t been discussed in much depth on here.

Up down up down...ever thought it’s moving sideways within a range? You clearly don’t understand what Avacta aim to achieve here on several fronts. Each to their own and good luck

The volatility in the sp is to be expected in between news. It seems like we got through the end of June nonsense (we already had the RNS re prototypes). Hopefully now we can turn our attention to the exciting news we should see in July:
BAMS test validation results
BAMS partnerships
LFT manufacturing partnerships and tech transfer start
Hopefully something comes of the Covid treatment

I think we will see higher highs and higher lows as we go forward. I can even see some of the derampers have now gone long. Ignore the new deramping accounts. Whose to say the same person even uses the same account each time? I wouldn’t waste your time trying to engage with them.